Breaking News

Financial Reports: Charles River 1Q

Preclinical revenues drop, offset by RMS uptick

Related CONTENT

Gil Roth05.03.12

Charles River Laboratories 1Q12

1Q Revenues: $286 million (flat)

1Q Earnings: $26 million (-16%)

Comments: Research Models and Services was up 6% to $183 million, driven by In Vitro and Avian businesses., for its best quarter since 2008. Preclinical Services dropped 9% to $103 million, with lower sales of biopharmaceutical services due to typically slow starts from large biopharma cients.

Related Searches

Suggested For You

Precision NanoSystems Announces Plans to Expand Global Headquarters

Precision NanoSystems Announces Plans to Expand Global Headquarters

Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer

Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer

Vectura, Incannex Enter Preclinical Services Agreement

Vectura, Incannex Enter Preclinical Services Agreement

Crown Bioscience Acquires OcellO

Crown Bioscience Acquires OcellO

Albumedix Extends Research Collaboration with Cobra Biologics

Albumedix Extends Research Collaboration with Cobra Biologics

Charles River Acquires Retrogenix

Charles River Acquires Retrogenix

Charles River Acquires CDMO Cognate BioServices

Charles River Acquires CDMO Cognate BioServices

Charles River Partners with JADE

Charles River Partners with JADE

Charles River Labs Acquires Distributed Bio

Charles River Labs Acquires Distributed Bio

Charles River Laboratories

Charles River Laboratories

PathoQuest, Charles River Expand Strategic Pact

PathoQuest, Charles River Expand Strategic Pact

Saneca Pharma Expands Services in Russia

Saneca Pharma Expands Services in Russia

Norgine Buys Merus Labs for $342M

Norgine Buys Merus Labs for $342M

Financial Report: AMRI

Financial Report: AMRI

Financial Report: Regeneron

Financial Report: Regeneron

Related Breaking News

Bio News | Breaking News | Clinical Trials | CRO News | Industry News | R&D

Cato SMS, Pharm-Olam Merge to Create Global Biopharma Services Company

Newly combined company positioned to serve small and mid-sized biopharmaceutical companies.
01.07.22
Breaking News | Clinical Trials

Pentarlandir Proves Effective Against COVID-19 Variants in Preclinical Studies

Costs for the drug are expected to be significantly lower than for Pfizer’s Paxlovid.
01.06.22
Breaking News | Clinical Trials | Drug Development | Trials & Filings

Jubilant Therapeutics Receives FDA Clearance for JBI-802 IND

Phase 1/2a trial designed to define the safety profile and preliminary activity of JBI-802 in participants with advanced solid tumors.
01.06.22
Breaking News | Clinical Trials | Collaborations & Alliances

Synairgen Partners with Ashfield Engage to Support the Commercialization of SNG001

Aims to bring innovative potential treatment to COVID-19 patients.
01.06.22
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News

Nasal Spray Corona Vaccine Enters Clinical Trial

Leiden Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine.
01.05.22
Breaking News | CRO News | Industry News | Preclinical Outsourcing

Altasciences Acquires Sinclair Research

Continues to expand preclinical platform.
01.05.22
Breaking News | Clinical Trials

Evotec Receives German Grant for Potential Therapy Against COVID-19

Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.
01.04.22
Breaking News | Clinical Trials | CRO News | Information Technology

Emmes Acquires CRO Institut Dr. Schauerte

Full-service, technology-oriented CRO specializes in late-phase, non-interventional, and post-market clinical follow-up studies.
01.04.22
Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development

Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance

To evaluate Orion's CCR5 antagonist, OB-002, in Evofem's Phexxi vaginal gel with the goal of developing a Multipurpose Prevention Technology for HIV.
12.20.21
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Industry News

ProBioGen’s GlymaxX Technology Reaches Phase III Development

Zymeworks recently announced a global Phase III clinical trial of zanidatamab in HER2‑expressing gastroesophageal cancer.
12.17.21
Breaking News | Clinical Trials

FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate

Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.
12.16.21
Breaking News | Clinical Trials | Collaborations & Alliances

NOVA Expands JINKO Platform Pact with Janssen

Implements its JINKO clinical trial simulation platform for the development of lung cancer models.
12.16.21
Breaking News | Clinical Trials

Calyx Extends Partnership with Leading CRO

Clinical trial management system delivers heightened data security, open connectivity and improved trial efficiencies.
12.14.21
Breaking News | cGMP Manufacture | Clinical Trials | CRO News | Drug Development

Thermo Fisher Scientific Completes PPD Acquisition

With the addition of PPD, Thermo Fisher will offer a comprehensive suite of services across the clinical development spectrum.
12.08.21
Breaking News | Clinical Trials | CRO News | Drug Development

Rho Acquires European CRO Dokumeds

Expands global reach and capabilities with complementary specialties and multinational footprint in Europe and beyond.
12.08.21